TROGARZO

NDC 62064-122 · Theratechnologies Inc.

Generic nameibalizumab

Dosage formINJECTION, SOLUTION

RouteINTRAVENOUS

Active ingredient(s)IBALIZUMAB

Strength150 mg/mL

Pharmacologic classAntibodies, Monoclonal, Humanized [CS], CD4-directed Antibody Interactions [MoA], CD4-directed Blocking Antibody [EPC], HIV 1 Post-attachment Fusion Inhibitors [MoA], Human Immunodeficiency Virus 1 Post-attachment Fusion Inhibitor [EPC]

Marketing categoryBLA

Packages

62064-122-02 — 2 VIAL, SINGLE-USE in 1 CARTON (62064-122-02) / 1.33 mL in 1 VIAL, SINGLE-USE (62064-122-01)

Billed under HCPCS

J1746 — Injection, ibalizumab-uiyk, 10 mg Medicare Part B payment limit (ASP + 6%): $79.51

From the FDA National Drug Code Directory, retrieved August 24, 2026. Product listings are submitted by labelers; FDA does not verify them.